# Johns Hopkins University Baltimore India Clinical Trail Unit (JHUBI CTU)

> **NIH NIH UM1** · JOHNS HOPKINS UNIVERSITY · 2024 · $2,176,002

## Abstract

JHUBI PROJECT SUMMARY
The proposed Johns Hopkins University Baltimore-India Clinical Trials Unit (JHUBI CTU) will combine three
highly productive Clinical Research Sites (CRSs): the Johns Hopkins University (JHU) CRS at the JHU School
of Medicine in Baltimore, the Byramji Jeejeebhoy Government Medical College-Johns Hopkins University
(BJGMC-JHU) CRS in Pune, India, and the Y.R. Gaitonde Centre for AIDS Research and Education (YRG
CARE) CRS in Chennai, India, committed to ending the HIV, TB and comorbidities epidemics. These sites
include the largest HIV care provider in Baltimore, the largest HIV and TB care and clinical research provider in
Pune, India, and the largest HIV prevention and treatment care and clinical research center in Chennai, India.
Two of these sites are currently affiliated with existing NIAID Networks (JHU site 201 and BJGMC-JHU site
31441), while YRG CARE is applying as a new site but has most of its staff and infrastructure that was
previously part of Network site 11701. All three of these sites have extensive, ongoing NIH-funded research
portfolios, and are affiliated with the Division of Infectious Diseases at the JHU School of Medicine in
Baltimore, which will serve as the CTU home. Over the past 25 years, these three sites have contributed
significantly to the science, populations, and management of studies sponsored by all of the existing DAIDS
Networks: 1) the AIDS Clinical Trials Group (ACTG); 2) the International Maternal Pediatric Adolescent AIDS
Clinical Trials Group (IMPAACT); 3) the HIV Prevention Trials Network (HPTN); 4) the Microbicides Trials
Network (MTN); and 5) the HIV Vaccine Trials Network (HVTN). Since December 2013, JHUBI CTU
investigators have led 10 ACTG, 7 IMPAACT, and 2 HPTN scientific and administrative committees; led 27
ACTG, 11 IMPAACT, 7 HPTN and 1 HVTN protocols; and authored 2,167 HIV, TB, hepatitis, and related
scientific publications, including 150 Network-related publications. In addition, the JHUBI CTU has enrolled and
followed 2,702 participants with >90% retention into ACTG, IMPAACT, and HPTN trials, and >30,000
participants into non-Network studies relevant to the next 7 years of DAIDS Network science. The JHUBI CTU
proposes to affiliate with all four DAIDS Networks: HIV Adult Therapeutics, Maternal Adolescent and Pediatric
Therapeutics, HIV Prevention, and HIV Vaccine. The JHUBI CTU will engage in the highest quality human
subjects research based on implementation of our Mission Statement: "To serve our communities in Baltimore
and India, the Johns Hopkins University Baltimore-India Clinical Trials Unit (JHUBI CTU) will develop and
provide access to the highest priority HIV prevention and treatment research. To support NIAID networks, the
JHUBI CTU will provide scientific leadership, access to key populations, and the most efficient and responsible
management of our clinical trials activities."

## Key facts

- **NIH application ID:** 10745672
- **Project number:** 5UM1AI069465-18
- **Recipient organization:** JOHNS HOPKINS UNIVERSITY
- **Principal Investigator:** Charles W. Flexner
- **Activity code:** UM1 (R01, R21, SBIR, etc.)
- **Funding institute:** NIH
- **Fiscal year:** 2024
- **Award amount:** $2,176,002
- **Award type:** 5
- **Project period:** 2007-02-05 → 2027-11-30

## Primary source

NIH RePORTER: https://reporter.nih.gov/project-details/10745672

## Citation

> US National Institutes of Health, RePORTER application 10745672, Johns Hopkins University Baltimore India Clinical Trail Unit (JHUBI CTU) (5UM1AI069465-18). Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/grant/nih/10745672. Licensed CC0.

---

*[NIH grants dataset](/datasets/nih-grants) · CC0 1.0*